Cargando…
Modulation of Gut Microbiota to Enhance Effect of Checkpoint Inhibitor Immunotherapy
Accumulating evidence demonstrated the crucial role of gut microbiota in many human diseases, including cancer. Checkpoint inhibitor therapy has emerged as a novel treatment and has been clinically accepted as a major therapeutic strategy for cancer. Gut microbiota is related to cancer and the effec...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8276067/ https://www.ncbi.nlm.nih.gov/pubmed/34267748 http://dx.doi.org/10.3389/fimmu.2021.669150 |
_version_ | 1783721840483500032 |
---|---|
author | Wu, Jianmin Wang, Shan Zheng, Bo Qiu, Xinyao Wang, Hongyang Chen, Lei |
author_facet | Wu, Jianmin Wang, Shan Zheng, Bo Qiu, Xinyao Wang, Hongyang Chen, Lei |
author_sort | Wu, Jianmin |
collection | PubMed |
description | Accumulating evidence demonstrated the crucial role of gut microbiota in many human diseases, including cancer. Checkpoint inhibitor therapy has emerged as a novel treatment and has been clinically accepted as a major therapeutic strategy for cancer. Gut microbiota is related to cancer and the effect of immune checkpoint inhibitors (ICIs), and supplement with specific bacterial species can restore or enhance the responses to the ICIs. Namely, specified bacteria can serve as the biomarkers for distinguishing the patient who will respond to ICIs and determine the effectiveness of ICIs, as well as predicting the efficacy of checkpoint inhibitor immunotherapy. Regardless of the significant findings, the relationship between gut microbiota and the effect of ICIs treatment needs a more thorough understanding to provide more effective therapeutic plans and reduce treatment complication. In this review, we summarized the role of gut microbiota played in immune system and cancer. We mainly focus on the relationship between gut microbiota and the checkpoint inhibitor immunotherapy. |
format | Online Article Text |
id | pubmed-8276067 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-82760672021-07-14 Modulation of Gut Microbiota to Enhance Effect of Checkpoint Inhibitor Immunotherapy Wu, Jianmin Wang, Shan Zheng, Bo Qiu, Xinyao Wang, Hongyang Chen, Lei Front Immunol Immunology Accumulating evidence demonstrated the crucial role of gut microbiota in many human diseases, including cancer. Checkpoint inhibitor therapy has emerged as a novel treatment and has been clinically accepted as a major therapeutic strategy for cancer. Gut microbiota is related to cancer and the effect of immune checkpoint inhibitors (ICIs), and supplement with specific bacterial species can restore or enhance the responses to the ICIs. Namely, specified bacteria can serve as the biomarkers for distinguishing the patient who will respond to ICIs and determine the effectiveness of ICIs, as well as predicting the efficacy of checkpoint inhibitor immunotherapy. Regardless of the significant findings, the relationship between gut microbiota and the effect of ICIs treatment needs a more thorough understanding to provide more effective therapeutic plans and reduce treatment complication. In this review, we summarized the role of gut microbiota played in immune system and cancer. We mainly focus on the relationship between gut microbiota and the checkpoint inhibitor immunotherapy. Frontiers Media S.A. 2021-06-29 /pmc/articles/PMC8276067/ /pubmed/34267748 http://dx.doi.org/10.3389/fimmu.2021.669150 Text en Copyright © 2021 Wu, Wang, Zheng, Qiu, Wang and Chen https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Wu, Jianmin Wang, Shan Zheng, Bo Qiu, Xinyao Wang, Hongyang Chen, Lei Modulation of Gut Microbiota to Enhance Effect of Checkpoint Inhibitor Immunotherapy |
title | Modulation of Gut Microbiota to Enhance Effect of Checkpoint Inhibitor Immunotherapy |
title_full | Modulation of Gut Microbiota to Enhance Effect of Checkpoint Inhibitor Immunotherapy |
title_fullStr | Modulation of Gut Microbiota to Enhance Effect of Checkpoint Inhibitor Immunotherapy |
title_full_unstemmed | Modulation of Gut Microbiota to Enhance Effect of Checkpoint Inhibitor Immunotherapy |
title_short | Modulation of Gut Microbiota to Enhance Effect of Checkpoint Inhibitor Immunotherapy |
title_sort | modulation of gut microbiota to enhance effect of checkpoint inhibitor immunotherapy |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8276067/ https://www.ncbi.nlm.nih.gov/pubmed/34267748 http://dx.doi.org/10.3389/fimmu.2021.669150 |
work_keys_str_mv | AT wujianmin modulationofgutmicrobiotatoenhanceeffectofcheckpointinhibitorimmunotherapy AT wangshan modulationofgutmicrobiotatoenhanceeffectofcheckpointinhibitorimmunotherapy AT zhengbo modulationofgutmicrobiotatoenhanceeffectofcheckpointinhibitorimmunotherapy AT qiuxinyao modulationofgutmicrobiotatoenhanceeffectofcheckpointinhibitorimmunotherapy AT wanghongyang modulationofgutmicrobiotatoenhanceeffectofcheckpointinhibitorimmunotherapy AT chenlei modulationofgutmicrobiotatoenhanceeffectofcheckpointinhibitorimmunotherapy |